Review: taking Xalatan and Alphagan p together


Summary

Drug interactions are reported among people who take Xalatan and Alphagan p together. This review analyzes the effectiveness and drug interactions between Xalatan and Alphagan p. It is created by eHealthMe based on reports of 1,349 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Xalatan and Alphagan p >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Xalatan

Xalatan has active ingredients of latanoprost. It is often used in glaucoma. (latest outcomes from Xalatan 14,358 users)

Alphagan P

Alphagan p has active ingredients of brimonidine tartrate. It is often used in glaucoma. (latest outcomes from Alphagan p 507 users)

On Jul, 25, 2016

1,349 people who take Xalatan, Alphagan P are studied.


Number of reports submitted per year:

Xalatan and Alphagan p drug interactions.

Drug effectiveness over time:

Xalatan:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 50.0% - (1 of 2 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 2 people)
  • 2 - 5 years: 0.0% - (0 of 4 people)
  • 5 - 10 years: 20.0% - (1 of 5 people)
  • 10+ years: 25.0% - (1 of 4 people)
  • not specified: 0.0% - (0 of 0 people)
Alphagan P:
  • < 1 month: 0.0% - (0 of 2 people)
  • 1 - 6 months: 0.0% - (0 of 2 people)
  • 6 - 12 months: 100.0% - (1 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 3 people)
  • 2 - 5 years: 0.0% - (0 of 2 people)
  • 5 - 10 years: 0.0% - (0 of 2 people)
  • 10+ years: 20.0% - (1 of 5 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Xalatan:
  • female: 20.0% - (2 of 10 people)
  • male: 14.0% - (1 of 7 people)
Alphagan P:
  • female: 11.0% - (1 of 9 people)
  • male: 12.0% - (1 of 8 people)

Drug effectiveness by age:

Xalatan:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 100.0% - (1 of 1 people)
  • 40-49: 50.0% - (1 of 2 people)
  • 50-59: 25.0% - (1 of 4 people)
  • 60+: 0.0% - (0 of 10 people)
Alphagan P:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 1 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 1 people)
  • 40-49: 50.0% - (1 of 2 people)
  • 50-59: 25.0% - (1 of 4 people)
  • 60+: 0.0% - (0 of 9 people)

Most common drug interactions over time *:

< 1 month:
  • drug ineffective
  • eye irritation
  • glaucoma
  • blindness transient
  • dry eye
  • eye disorder
  • eye haemorrhage
  • eye pain
  • eyelid oedema
  • hypersensitivity
1 - 6 months:
  • pancytopenia
  • pyrexia
  • bone marrow failure
  • inflammation
  • cough
  • tonsillitis
  • abnormal dreams
  • dyspnoea
  • hypersensitivity
  • nasal congestion
6 - 12 months:
  • abnormal dreams
  • cough
  • dyspnoea
  • nasal congestion
  • tinnitus
  • growth of eyelashes
  • pain
  • urinary tract malformation
  • ageusia
  • anosmia
1 - 2 years:
  • nasal congestion
  • dyspnoea
  • abnormal dreams
  • cough
  • growth of eyelashes
  • intraocular pressure increased
  • pain
  • tinnitus
  • blepharitis
  • conjunctival haemorrhage
2 - 5 years:
  • depression
  • ocular hyperaemia
  • tinnitus
  • abnormal dreams
  • amnesia
  • arrhythmia
  • cough
  • drug hypersensitivity
  • dyspepsia
  • dyspnoea
5 - 10 years:
  • arthritis
  • back pain
  • blood pressure increased
  • bunion
  • deafness neurosensory
  • depression
  • cataract
  • drug ineffective
  • fatigue
  • intraocular pressure increased
10+ years:
  • eyelid margin crusting
  • pressure sore
  • asthenia
  • muscular weakness
  • nausea
  • tinnitus
not specified:
  • intraocular pressure increased
  • glaucoma
  • dyspnoea
  • visual acuity reduced
  • drug ineffective
  • eye irritation
  • fatigue
  • pain
  • asthenia
  • dizziness

Most common drug interactions by gender *:

female:
  • dyspnoea
  • intraocular pressure increased
  • visual acuity reduced
  • fatigue
  • pain
  • drug ineffective
  • asthenia
  • glaucoma
  • constipation
  • nausea
male:
  • intraocular pressure increased
  • glaucoma
  • eye irritation
  • visual acuity reduced
  • dyspnoea
  • drug ineffective
  • ocular hyperaemia
  • cardiac failure congestive
  • pain
  • dizziness

Most common drug interactions by age *:

0-1:
  • apnoea
  • bradycardia neonatal
  • cyanosis neonatal
  • depressed level of consciousness
  • developmental delay
  • feeding problem in newborn
  • hypotension
  • hypothermia
  • hypotonia neonatal
  • iris disorder
10-19:
  • antibody test abnormal
  • coombs test positive
  • glaucoma aggravated
  • haemoglobin decreased
  • immunodeficiency
20-29:
  • drug ineffective
  • vitreous haemorrhage
  • corneal oedema
  • intraocular pressure increased
  • vision blurred
  • blood pressure decreased
  • dyspnoea
  • feeling abnormal
  • hypertension
  • retinal tear
30-39:
  • drug ineffective
  • scotoma
  • visual field defect
  • corneal oedema
  • disease progression
  • herpes simplex ophthalmic
  • intraocular pressure increased
  • visual acuity reduced
  • eye disorder
  • abnormal dreams
40-49:
  • intraocular pressure increased
  • eye irritation
  • visual acuity reduced
  • blindness unilateral
  • drug ineffective
  • intestinal obstruction
  • ocular hyperaemia
  • white blood cell count increased
  • eye pain
  • abdominal pain upper
50-59:
  • dyspnoea
  • pain
  • glaucoma
  • nausea
  • visual acuity reduced
  • anaemia
  • fatigue
  • pneumonia
  • vomiting
  • abdominal pain upper
60+:
  • intraocular pressure increased
  • visual acuity reduced
  • eye irritation
  • drug ineffective
  • fatigue
  • vision blurred
  • asthenia
  • pyrexia
  • dizziness
  • glaucoma

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Xalatan and Alphagan p?

You may be interested in these reviews

More reviews for: Xalatan, Alphagan p

On eHealthMe, Xalatan (latanoprost) is often used to treat glaucoma. Alphagan p (brimonidine tartrate) is often used to treat glaucoma. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.